Protein Engineering vol. 3 no. 8 pp. 713-719, 1990
© 1990 Oxford University Press
RESEARCH-ARTICLE |
Mutational analysis of structure—activity relationships in human tumor necrosis factor-alpha
Research Laboratories, Dainippon Pharmaceutical Co. Ltd 33-94, Enoki, Suita, Osaka 564, Japan
To determine the region of human tumor necrosis factor-alpha (TNF-
), essential for cytotoxic activity against mouse L-M cells, single amino-acid-substituted TNF- mutant proteins (muteins) were produced in Escherichia coli by protein engineering techniques. An expression plasmid for TNF- was mutagenized by passage through an E.coli mutD5 mutator strain and by oligonucleotide-directed mutagenesis. Approximately 100 single amino-acid-substituted TNF- muteins were produced and assayed for cytotoxic activity. The cytotoxic activities of purified TNF- muteins, e.g. TNF-31T, -32Y, -82D, -85H, -115L, -141Y, -144K and -146E, were < 1% of that of parent TNF-. These results indicate that the integrity of at least four distinct regions of the TNF- molecule is required for full biological activity. These regions are designated as follows: region I, from position 30 to 32; region II, from position 82 to 89; region III, from position 115 to 117; region FV, from position 141 to 146. In addition, TNF-141Y could not completely compete with parent TNF- for binding to the receptor. This demonstrates that region IV, and at least aspartk acid at position 141, must be involved in the TNF receptor binding site.
Keywords: cytotoxic activity/human tumor necrosis factor-alpha/mutD mutagenesis/oligonucleotide-directed mutagenesis/receptor binding activity
Received December 20, 1989; accepted April 4, 1990.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Rutschmann, K. Hoebe, J. Zalevsky, X. Du, N. Mann, B. I. Dahiyat, P. Steed, and B. Beutler PanR1, a Dominant Negative Missense Allele of the Gene Encoding TNF-{alpha} (Tnf), Does Not Impair Lymphoid Development. J. Immunol., June 15, 2006; 176(12): 7525 - 7532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shibata, Y. Yoshioka, S. Ikemizu, K. Kobayashi, Y. Yamamoto, Y. Mukai, T. Okamoto, M. Taniai, M. Kawamura, Y. Abe, et al. Functionalization of Tumor Necrosis Factor-{alpha} Using Phage Display Technique and PEGylation Improves Its Antitumor Therapeutic Window Clin. Cancer Res., December 15, 2004; 10(24): 8293 - 8300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L Gavin, D. Ait-Azzouzene, C. F. Ware, and D. Nemazee {Delta}BAFF, an Alternate Splice Isoform That Regulates Receptor Binding and Biopresentation of the B Cell Survival Cytokine, BAFF J. Biol. Chem., October 3, 2003; 278(40): 38220 - 38228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Steed, M. G. Tansey, J. Zalevsky, E. A. Zhukovsky, J. R. Desjarlais, D. E. Szymkowski, C. Abbott, D. Carmichael, C. Chan, L. Cherry, et al. Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants Science, September 26, 2003; 301(5641): 1895 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-S. Cha, J.-S. Kim, H.-S. Cho, N.-K. Shin, W. Jeong, H.-C. Shin, Y. J. Kim, J. H. Hahn, and B.-H. Oh High Resolution Crystal Structure of a Human Tumor Necrosis Factor-alpha Mutant with Low Systemic Toxicity J. Biol. Chem., January 23, 1998; 273(4): 2153 - 2160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Orlinick, K. B. Elkon, and M. V. Chao Separate Domains of the Human Fas Ligand Dictate Self-association and Receptor Binding J. Biol. Chem., December 19, 1997; 272(51): 32221 - 32229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yone, S. Bajard, N. Tsunekawa, and J. Suzuki Epitopic Regions for Antibodies against Tumor Necrosis Factor alpha J. Biol. Chem., August 18, 1995; 270(33): 19509 - 19515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Lucas, S Magez, R De Leys, L Fransen, J. Scheerlinck, M Rampelberg, E Sablon, and P De Baetselier Mapping the lectin-like activity of tumor necrosis factor Science, February 11, 1994; 263(5148): 814 - 817. [Abstract] [PDF]
|
|